Recordati, the Italian pharmaceutical company, finds itself at the center of a boardroom battle over a €10.7 billion take-private bid. While six of ten directors have endorsed the €51.29-per-share cash offer from private equity firm CVC Capital Partners and Belgian holding company Groupe Bruxelles Lambert (GBL), four independent directors have publicly dissented, calling the price “inadequate and not fair.”
The Offer and the Split
On Wednesday, Recordati disclosed that a majority of its board supports the €51.29 per share bid from CVC and GBL. CVC already controls 46.8% of the company through an investment vehicle and first signaled its intention to buy the rest in March. The offer values the entire company at roughly €10.7 billion.
However, four independent directors disagreed, arguing that the price does not reflect the company's true worth, even as they acknowledged the logic of taking the company private. This rare public dissent adds a layer of uncertainty to what might otherwise be a straightforward deal.
The market, for now, is treating the offer as the main reference point. Recordati shares closed at €51.30, just one cent above the bid price, indicating that investors see a high probability the deal will close at or near this level.
What This Means for Investors
When a stock trades right on top of a cash offer, the remaining “spread” — the difference between the share price and the bid — becomes a live read on two things: the odds of completion and how long it may take to get paid. With Recordati at €51.30 against €51.29, most of the straightforward upside is gone. The stock’s near-term moves will now be driven by the deal's outcome rather than the company's underlying business performance.
The 6-4 board vote keeps one door open. A public dissent from independent directors is a rare, on-the-record signal that could support calls for a higher price, even with CVC already owning a large stake. That means the setup is unusually binary: the stock could close around €51.29 if the deal goes through, or drop if talks stall. Any meaningful upside would likely require a revised bid rather than a normal shift in sentiment about Recordati’s fundamentals.
For everyday investors, this situation highlights the dynamics of take-private deals, especially when a major shareholder is also the buyer. When a would-be buyer already holds a big stake, it can be harder for other bidders to emerge, and minority shareholders often focus on whether the price fully reflects the company’s value. The independent directors' dissent may embolden other shareholders to push for a better offer, but there is no guarantee of success.
Broader Context
Take-private transactions have become more common in recent years, as private equity firms and other investors seek to acquire public companies they believe are undervalued by the market. Similar large-scale buyout offers have been seen in other sectors, such as the reported $53 billion bid to take PayPal private and Uber's talks to buy Delivery Hero for €12.5 billion. These deals often involve complex negotiations and can create uncertainty for existing shareholders.
Recordati, founded in 1926, is a well-known Italian drugmaker with a focus on specialty pharmaceuticals and rare diseases. The company has a strong portfolio of products and a solid track record of growth, which may explain why some directors believe the bid undervalues the business.
What to Watch Next
Investors will be watching for any developments that could change the deal's trajectory. A revised offer from CVC and GBL is possible, especially if enough shareholders express dissatisfaction. Alternatively, the deal could proceed at the current price, leaving those who bought at higher levels with a loss. The independent directors' stance may also attract regulatory scrutiny or encourage other potential bidders to step forward, though CVC's existing stake makes a competing bid less likely.
For now, Recordati's stock is essentially a bet on the deal's completion. As with any take-private situation, investors should be aware of the risks: if the deal falls through, the stock could drop significantly, as it would then trade based on the company's standalone prospects rather than the bid price. The broader market environment, including recent mixed signals from inflation data and geopolitical concerns, could also influence investor sentiment.
In the end, the Recordati board split is a reminder that even when a deal seems close to done, the final price is not always set in stone. For everyday investors, the key takeaway is to understand the dynamics at play and to recognize that in such situations, the stock price may not reflect the company's long-term value but rather the probability of a specific transaction closing.
